Safety Profile of Good Manufacturing Practice Manufactured Interferon γ-Primed Mesenchymal Stem/Stromal Cells for Clinical Trials

Stem Cells Translational Medicine

Volumn 6, Issue 10, 2017, Pages 1868-1879

  Guess, Adam J ^a   Daneault, Beth ^b   Wang, Rongzhang ^b   Bradbury, Hillary ^b   La Perle, Krista M D ^a   Fitch, James ^a   Hedrick, Sheri L ^a   Hamelberg, Elizabeth ^a   Astbury, Caroline ^c   White, Peter ^a,b   Overolt, Kathleen ^a,b   Rangarajan, Hemalatha ^a,b   Abu Arja, Rolla ^a,b   Devine, Steven M ^b   Otsuru, Satoru ^a   Dominici, Massimo ^d   O'Donnell, Lynn ^b   Horwitz, Edwin M ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Good Manufacturing Practice (GMP); Interferon gamma; Mesenchymal stem cells; Mesenchymal stromal cells (MSC)

Indexed keywords

GAMMA INTERFERON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOINFORMATICS; CELL DIFFERENTIATION ASSAY; COLONY FORMATION; CONTROLLED STUDY; CRYOPRESERVATION; ENGRAFTMENT; FLOW CYTOMETRY; GENE EXPRESSION; GOOD MANUFACTURING PRACTICE; HEMATOPOIETIC CELL; IMMUNOMODULATION; KARYOTYPING; MALIGNANT TRANSFORMATION; MESENCHYMAL STEM CELL; MESENCHYMAL STROMA CELL; METAPLASIA; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; ANIMAL; C57BL MOUSE; CELL CULTURE; CELL REPROGRAMMING TECHNIQUE; CLINICAL TRIAL (TOPIC); CYTOLOGY; DRUG EFFECT; HUMAN; MESENCHYMAL STEM CELL TRANSPLANTATION; PRACTICE GUIDELINE; PROCEDURES; STANDARDS;

ANIMALS; CELLS, CULTURED; CELLULAR REPROGRAMMING TECHNIQUES; CLINICAL TRIALS AS TOPIC; HUMANS; INTERFERON-GAMMA; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; MICE; MICE, INBRED C57BL; PRACTICE GUIDELINES AS TOPIC;

EID: 85030216725     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.1002/sctm.16-0485     Document Type: Article

References (30)

1. Squillaro T, Peluso G, Galderisi U. Clinical trials with mesenchymal stem cells: An update. Cell Transplant 2016;25:829–848.
2. Galipeau J. The mesenchymal stromal cells dilemma–does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road? Cytotherapy 2013;15:2–8.
3. Sivanathan KN, Gronthos S, Rojas-Canales D et al. Interferon-gamma modification of mesenchymal stem cells: Implications of autologous and allogeneic mesenchymal stem cell therapy in allotransplantation. Stem Cell Rev 2014;10:351–375.
4. Sivanathan KN, Rojas-Canales DM, Hope CM et al. Interleukin-17A-induced human mesenchymal stem cells are superior modulators of immunological function. Stem Cells 2015;33:2850–2863.
5. Francois M, Copland IB, Yuan S et al. Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-gamma licensing. Cytotherapy 2012;14:147–152.
6. Martinez C, Hofmann TJ, Marino R et al. Human bone marrow mesenchymal stromal cells express the neural ganglioside GD2: A novel surface marker for the identification of MSCs. Blood 2007;109:4245–4248.
7. Dominici M, Tadjali M, Kepes S et al. Transgenic mice with pancellular enhanced green fluorescent protein expression in primitive hematopoietic cells and all blood cell progeny. Genesis 2005;42:17–22.
8. Horwitz EM, Gordon PL, Koo WKK et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad Sci USA 2002;99:8932–8937.
9. Dominici M, Pritchard C, Garlits JE et al. Hematopoietic cells and osteoblasts are derived from a common marrow progenitor after bone marrow transplantation. Proc Natl Acad Sci USA 2004;101:11761–11766.
10. Francois S, Bensidhoum M, Mouiseddine M et al. Local irradiation induces not only homing of human mesenchymal stem cells (hMSC) at exposed sites but promotes their widespread engraftment to multiple organs: A study of their quantitative distribution following irradiation damages. Stem Cells 2006;24:1020–1029.
11. Seabright M. A rapid banding technique for human chromosomes. Lancet 1971;2:971–972.
12. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 2014;15:550.
13. Otsuru S, Hofmann TJ, Raman P et al. Genomic and functional comparison of mesenchymal stromal cells prepared using two isolation methods. Cytotherapy 2015;17:262–270.
14. Veenstra RG, Flynn R, Kreymborg K et al. B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality. Blood 2015;125:3335–3346.
15. Johns JL, Christopher MM. Extramedullary hematopoiesis: A new look at the underlying stem cell niche, theories of development, and occurrence in animals. Vet Pathol 2012;49:508–523.
16. Dutia BM, Clarke CJ, Allen DJ et al. Pathological changes in the spleens of gamma interferon receptor-deficient mice infected with murine gammaherpesvirus: A role for CD8 T cells. J Virol 1997;71:4278–4283.
17. Seely JC. Kidney. In: Maronpot RR, ed. Pathology of the Mouse. St. Louis, Missouri: Cache River Press, 1999:207–234.
18. Dixon D, Herbert RA, Sills RC et al. In: Maronpot RR, ed. Pathology of the Mouse. St. Louis, Missouri: Cache River Press, 1999:293–332.
19. Otsuru S, Hofmann TJ, Olson TS et al. Improved isolation and expansion of bone marrow mesenchymal stromal cells using a novel marrow filter device. Cytotherapy 2013;15:146–153.
20. Grisendi G, Anneren C, Cafarelli L et al. GMP-manufactured density gradient media for optimized mesenchymal stromal/stem cell isolation and expansion. Cytotherapy 2010;12:466–477.
21. Otsuru S, Gordon PL, Shimono K et al. Transplanted bone marrow mononuclear cells and mscs impart clinical benefit to children with osteogenesis imperfecta through different mechanisms. Blood 2012;120:1933–1941.
22. Sensebe L, Fleury-Cappellesso S. Biodistribution of mesenchymal stem/stromal cells in a preclinical setting. Stem Cells Int 2013;2013:678063.
23. Allers C, Sierralta WD, Neubauer S et al. Dynamic of distribution of human bone marrow-derived mesenchymal stem cells after transplantation into adult unconditioned mice. Transplantation 2004;78:503–508.
24. de Bruin AM, Voermans C, Nolte MA. Impact of interferon-gamma on hematopoiesis. Blood 2014;124:2479–2486.
25. Lin FC, Karwan M, Saleh B et al. IFN-gamma causes aplastic anemia by altering hematopoietic stem/progenitor cell composition and disrupting lineage differentiation. Blood 2014;124:3699–3708.
26. Davoodi P, Mahesh PA, Holla AD et al. Serum levels of interleukin-13 and interferon-gamma from adult patients with asthma in Mysore. Cytokine 2012;60:431–437.
27. DiCarlo J, Agarwal-Hashmi R, Shah A et al. Cytokine and chemokine patterns across 100 days after hematopoietic stem cell transplantation in children. Biol Blood Marrow Transplant 2014;20:361–369.
28. Gholamrezanezhad A, Mirpour S, Bagheri M et al. In vivo tracking of 111In-oxine labeled mesenchymal stem cells following infusion in patients with advanced cirrhosis. Nucl Med Biol 2011;38:961–967.
29. Briquet A, Gregoire C, Comblain F et al. Human bone marrow, umbilical cord or liver mesenchymal stromal cells fail to improve liver function in a model of CCl4-induced liver damage in NOD/SCID/IL-2Rgamma(null) mice. Cytotherapy 2014;16:1511–1518.
30. Cesta MF, Herbert RA, Brix A et al. eds. National Toxicology Program Nonneoplastic Lesion Atlas. Available at http://ntp.niehs.nih.gov/nnl/guide/index.htm. Accessed September 6, 2016.